Literature DB >> 17711986

Sensitivity to metabolic signals in late-gestation growth-restricted fetuses from rapidly growing adolescent sheep.

Jacqueline M Wallace1, John S Milne, Raymond P Aitken, William W Hay.   

Abstract

Fetal sensitivity to insulin and glucose was investigated during fetal hyperinsulinemic-euglycemic (HI-euG, n = 18) and hyperglycemic-euinsulinemic (HG-euI, n = 12) clamps. Singleton bearing adolescent ewes were fed high (H) or control (C) nutrient intakes to induce compromised or normal placental/fetal size, respectively. Catheters were inserted in the umbilical vein (v), fetal artery, (a) and veins, and studies were conducted between day 126 and 133 of gestation. Umbilical blood flow (UmBF) was determined by the steady-state transplacental diffusion technique using (3)H(2)O, and glucose fluxes were quantified by the Fick principle. For the HI-euG study, fetal glucose utilization was measured at spontaneously occurring fetal insulin concentrations and two additional higher levels, whereas fetal glucose was clamped at the initial baseline level. For the HG-euI study, fetal insulin was suppressed by somatostatin infusion, and fetal glucose utilization was determined at baseline (before somatostatin) glucose concentrations, and at 150 and 200% of this value. Placentome weight (219 vs. 395 g), fetal weight (2,965 vs. 4,373 g), and UmBF (519 vs. 794 ml/min) were lower (P < 0.001) in H than in C groups. Relative to control fetuses, glucose extraction (G[v - a]/G[v] x 100) in the nonperturbed state was higher (21.7 vs. 15.9%) in growth-restricted fetuses despite lower glucose (0.78 vs. 1.05 micromol/ml) and insulin (8.5 vs. 16.9 microU/ml) concentrations (all P < 0.001). During the HI-euG study, total fetal glucose utilization rate increased in response to higher insulin concentrations (65 and 64% in H and C groups). Similarly during the HG-euI study, a twofold increase in glucose supply increased fetal glucose utilization by 41 and 44% in H and C groups, respectively. Throughout both studies, absolute total fetal glucose utilization rates were reduced in H vs. C groups (P < 0.01) but were similar when expressed per kilogram fetus (HI-euG: 34.7, 49.5, and 57.5 in H vs. 34.7, 51.2, and 56.1 micromol.min(-1).kg(-1) in C, HG-euI: 28.7, 35.7, and 40.8 in H vs. 32.9, 34.5, and 43.8 micromol.min(-1).kg(-1) in C). These normal body weight-specific metabolic responses to short-term experimental increases in plasma insulin and glucose in response to chronic IUGR indicate maintained mechanisms of insulin action and glucose uptake/utilization capacity, which, if persistent, might predispose such IUGR offspring to excessive energy deposition in later life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17711986     DOI: 10.1152/ajpendo.00294.2007

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

1.  Prolonged infusion of amino acids increases leucine oxidation in fetal sheep.

Authors:  Anne M Maliszewski; Monika M Gadhia; Meghan C O'Meara; Stephanie R Thorn; Paul J Rozance; Laura D Brown
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-27       Impact factor: 4.310

2.  Acute supplementation of amino acids increases net protein accretion in IUGR fetal sheep.

Authors:  Laura D Brown; Paul J Rozance; Stephanie R Thorn; Jacob E Friedman; William W Hay
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-05-29       Impact factor: 4.310

Review 3.  Describing hypoglycemia--definition or operational threshold?

Authors:  Paul J Rozance; William W Hay
Journal:  Early Hum Dev       Date:  2010-05-31       Impact factor: 2.079

4.  Intrauterine growth-restricted sheep fetuses exhibit smaller hindlimb muscle fibers and lower proportions of insulin-sensitive Type I fibers near term.

Authors:  Dustin T Yates; Caitlin N Cadaret; Kristin A Beede; Hannah E Riley; Antoni R Macko; Miranda J Anderson; Leticia E Camacho; Sean W Limesand
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-06       Impact factor: 3.619

5.  Differential effects of intrauterine growth restriction and a hypersinsulinemic-isoglycemic clamp on metabolic pathways and insulin action in the fetal liver.

Authors:  Amanda K Jones; Laura D Brown; Paul J Rozance; Natalie J Serkova; William W Hay; Jacob E Friedman; Stephanie R Wesolowski
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-02-13       Impact factor: 3.619

6.  Peripheral insulin resistance and impaired insulin signaling contribute to abnormal glucose metabolism in preterm baboons.

Authors:  Cynthia L Blanco; Lisa L McGill-Vargas; Amalia Gastaldelli; Steven R Seidner; Donald C McCurnin; Michelle M Leland; Diana G Anzueto; Marney C Johnson; Hanyu Liang; Ralph A DeFronzo; Nicolas Musi
Journal:  Endocrinology       Date:  2015-01-05       Impact factor: 4.736

7.  Skeletal muscle protein accretion rates and hindlimb growth are reduced in late gestation intrauterine growth-restricted fetal sheep.

Authors:  Paul J Rozance; Laura Zastoupil; Stephanie R Wesolowski; David A Goldstrohm; Brittany Strahan; Melanie Cree-Green; Melinda Sheffield-Moore; Giacomo Meschia; William W Hay; Randall B Wilkening; Laura D Brown
Journal:  J Physiol       Date:  2017-10-26       Impact factor: 5.182

8.  Maternal obesity impairs fetal cardiomyocyte contractile function in sheep.

Authors:  Qiurong Wang; Chaoqun Zhu; Mingming Sun; Rexiati Maimaiti; Stephen P Ford; Peter W Nathanielsz; Jun Ren; Wei Guo
Journal:  FASEB J       Date:  2018-10-05       Impact factor: 5.191

9.  American Pediatric Society presidential address 2008: research in early life - benefit and promise.

Authors:  William W Hay
Journal:  Pediatr Res       Date:  2009-01       Impact factor: 3.756

10.  Glucose replacement to euglycemia causes hypoxia, acidosis, and decreased insulin secretion in fetal sheep with intrauterine growth restriction.

Authors:  Paul J Rozance; Sean W Limesand; James S Barry; Laura D Brown; William W Hay
Journal:  Pediatr Res       Date:  2009-01       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.